MRIoA’s High-Cost Specialty Drug Review allows health plans, TPAs and PBMs to leverage MRIoA’s specialist MDs to ensure use of evidence-based guidelines for high-cost drugs in treating medical conditions where lower-cost drug alternatives are available.